Global Wet Age-Related Macular Degeneration Treatment Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Page: 94
Published Date: 20 Jan 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Wet Age-Related Macular Degeneration Treatment market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The most common treatment doctors use to slow vision loss from wet AMD is called anti-VEGF injections. These medicines help stop bleeding and leaking from blood vessels in the back of your eye. Most people with wet AMD will get anti-VEGF injections as their only treatment.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Wet Age-Related Macular Degeneration Treatment industry chain, the market status of Hospital (Lucentis, Eylea), Clinic (Lucentis, Eylea), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Wet Age-Related Macular Degeneration Treatment.
Regionally, the report analyzes the Wet Age-Related Macular Degeneration Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Wet Age-Related Macular Degeneration Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Wet Age-Related Macular Degeneration Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Wet Age-Related Macular Degeneration Treatment industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Lucentis, Eylea).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Wet Age-Related Macular Degeneration Treatment market.
Regional Analysis: The report involves examining the Wet Age-Related Macular Degeneration Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Wet Age-Related Macular Degeneration Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Wet Age-Related Macular Degeneration Treatment:
Company Analysis: Report covers individual Wet Age-Related Macular Degeneration Treatment manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Wet Age-Related Macular Degeneration Treatment This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Wet Age-Related Macular Degeneration Treatment. It assesses the current state, advancements, and potential future developments in Wet Age-Related Macular Degeneration Treatment areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Wet Age-Related Macular Degeneration Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Wet Age-Related Macular Degeneration Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Lucentis
Eylea
Avastin
Others
Market segment by Application
Hospital
Clinic
Other
Major players covered
Roche
Novartis
Regeneron Pharmaceuticals
Bayer HealthCare
Kanghong Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Wet Age-Related Macular Degeneration Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Wet Age-Related Macular Degeneration Treatment, with price, sales, revenue and global market share of Wet Age-Related Macular Degeneration Treatment from 2019 to 2024.
Chapter 3, the Wet Age-Related Macular Degeneration Treatment competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Wet Age-Related Macular Degeneration Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Wet Age-Related Macular Degeneration Treatment market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Wet Age-Related Macular Degeneration Treatment.
Chapter 14 and 15, to describe Wet Age-Related Macular Degeneration Treatment sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Wet Age-Related Macular Degeneration Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Lucentis
1.3.3 Eylea
1.3.4 Avastin
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Wet Age-Related Macular Degeneration Treatment Market Size & Forecast
1.5.1 Global Wet Age-Related Macular Degeneration Treatment Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Wet Age-Related Macular Degeneration Treatment Sales Quantity (2019-2030)
1.5.3 Global Wet Age-Related Macular Degeneration Treatment Average Price (2019-2030)
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Wet Age-Related Macular Degeneration Treatment Product and Services
2.1.4 Roche Wet Age-Related Macular Degeneration Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Wet Age-Related Macular Degeneration Treatment Product and Services
2.2.4 Novartis Wet Age-Related Macular Degeneration Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Novartis Recent Developments/Updates
2.3 Regeneron Pharmaceuticals
2.3.1 Regeneron Pharmaceuticals Details
2.3.2 Regeneron Pharmaceuticals Major Business
2.3.3 Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Product and Services
2.3.4 Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.4 Bayer HealthCare
2.4.1 Bayer HealthCare Details
2.4.2 Bayer HealthCare Major Business
2.4.3 Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Product and Services
2.4.4 Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Bayer HealthCare Recent Developments/Updates
2.5 Kanghong Pharma
2.5.1 Kanghong Pharma Details
2.5.2 Kanghong Pharma Major Business
2.5.3 Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Product and Services
2.5.4 Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Kanghong Pharma Recent Developments/Updates
3.1 Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Manufacturer (2019-2024)
3.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Manufacturer (2019-2024)
3.3 Global Wet Age-Related Macular Degeneration Treatment Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Wet Age-Related Macular Degeneration Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Wet Age-Related Macular Degeneration Treatment Manufacturer Market Share in 2023
3.4.2 Top 6 Wet Age-Related Macular Degeneration Treatment Manufacturer Market Share in 2023
3.5 Wet Age-Related Macular Degeneration Treatment Market: Overall Company Footprint Analysis
3.5.1 Wet Age-Related Macular Degeneration Treatment Market: Region Footprint
3.5.2 Wet Age-Related Macular Degeneration Treatment Market: Company Product Type Footprint
3.5.3 Wet Age-Related Macular Degeneration Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Wet Age-Related Macular Degeneration Treatment Market Size by Region
4.1.1 Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2019-2030)
4.1.2 Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2019-2030)
4.1.3 Global Wet Age-Related Macular Degeneration Treatment Average Price by Region (2019-2030)
4.2 North America Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030)
4.3 Europe Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030)
4.4 Asia-Pacific Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030)
4.5 South America Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030)
4.6 Middle East and Africa Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030)
5.1 Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2030)
5.2 Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Type (2019-2030)
5.3 Global Wet Age-Related Macular Degeneration Treatment Average Price by Type (2019-2030)
6.1 Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2030)
6.2 Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Application (2019-2030)
6.3 Global Wet Age-Related Macular Degeneration Treatment Average Price by Application (2019-2030)
7.1 North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2030)
7.2 North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2030)
7.3 North America Wet Age-Related Macular Degeneration Treatment Market Size by Country
7.3.1 North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2030)
7.3.2 North America Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8.1 Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2030)
8.2 Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2030)
8.3 Europe Wet Age-Related Macular Degeneration Treatment Market Size by Country
8.3.1 Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2030)
8.3.2 Europe Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9.1 Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Wet Age-Related Macular Degeneration Treatment Market Size by Region
9.3.1 Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10.1 South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2030)
10.2 South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2030)
10.3 South America Wet Age-Related Macular Degeneration Treatment Market Size by Country
10.3.1 South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2030)
10.3.2 South America Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11.1 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Market Size by Country
11.3.1 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12.1 Wet Age-Related Macular Degeneration Treatment Market Drivers
12.2 Wet Age-Related Macular Degeneration Treatment Market Restraints
12.3 Wet Age-Related Macular Degeneration Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13.1 Raw Material of Wet Age-Related Macular Degeneration Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Wet Age-Related Macular Degeneration Treatment
13.3 Wet Age-Related Macular Degeneration Treatment Production Process
13.4 Wet Age-Related Macular Degeneration Treatment Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Wet Age-Related Macular Degeneration Treatment Typical Distributors
14.3 Wet Age-Related Macular Degeneration Treatment Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Wet Age-Related Macular Degeneration Treatment Product and Services
Table 6. Roche Wet Age-Related Macular Degeneration Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Roche Recent Developments/Updates
Table 8. Novartis Basic Information, Manufacturing Base and Competitors
Table 9. Novartis Major Business
Table 10. Novartis Wet Age-Related Macular Degeneration Treatment Product and Services
Table 11. Novartis Wet Age-Related Macular Degeneration Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Novartis Recent Developments/Updates
Table 13. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Regeneron Pharmaceuticals Major Business
Table 15. Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Product and Services
Table 16. Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Regeneron Pharmaceuticals Recent Developments/Updates
Table 18. Bayer HealthCare Basic Information, Manufacturing Base and Competitors
Table 19. Bayer HealthCare Major Business
Table 20. Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Product and Services
Table 21. Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Bayer HealthCare Recent Developments/Updates
Table 23. Kanghong Pharma Basic Information, Manufacturing Base and Competitors
Table 24. Kanghong Pharma Major Business
Table 25. Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Product and Services
Table 26. Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Kanghong Pharma Recent Developments/Updates
Table 28. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 29. Global Wet Age-Related Macular Degeneration Treatment Revenue by Manufacturer (2019-2024) & (USD Million)
Table 30. Global Wet Age-Related Macular Degeneration Treatment Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 31. Market Position of Manufacturers in Wet Age-Related Macular Degeneration Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 32. Head Office and Wet Age-Related Macular Degeneration Treatment Production Site of Key Manufacturer
Table 33. Wet Age-Related Macular Degeneration Treatment Market: Company Product Type Footprint
Table 34. Wet Age-Related Macular Degeneration Treatment Market: Company Product Application Footprint
Table 35. Wet Age-Related Macular Degeneration Treatment New Market Entrants and Barriers to Market Entry
Table 36. Wet Age-Related Macular Degeneration Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 37. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2019-2024) & (K Units)
Table 38. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2025-2030) & (K Units)
Table 39. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2019-2024) & (USD Million)
Table 40. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2025-2030) & (USD Million)
Table 41. Global Wet Age-Related Macular Degeneration Treatment Average Price by Region (2019-2024) & (US$/Unit)
Table 42. Global Wet Age-Related Macular Degeneration Treatment Average Price by Region (2025-2030) & (US$/Unit)
Table 43. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2024) & (K Units)
Table 44. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2025-2030) & (K Units)
Table 45. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Type (2019-2024) & (USD Million)
Table 46. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Type (2025-2030) & (USD Million)
Table 47. Global Wet Age-Related Macular Degeneration Treatment Average Price by Type (2019-2024) & (US$/Unit)
Table 48. Global Wet Age-Related Macular Degeneration Treatment Average Price by Type (2025-2030) & (US$/Unit)
Table 49. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2024) & (K Units)
Table 50. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2025-2030) & (K Units)
Table 51. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Application (2019-2024) & (USD Million)
Table 52. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Application (2025-2030) & (USD Million)
Table 53. Global Wet Age-Related Macular Degeneration Treatment Average Price by Application (2019-2024) & (US$/Unit)
Table 54. Global Wet Age-Related Macular Degeneration Treatment Average Price by Application (2025-2030) & (US$/Unit)
Table 55. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2024) & (K Units)
Table 56. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2025-2030) & (K Units)
Table 57. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2024) & (K Units)
Table 58. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2025-2030) & (K Units)
Table 59. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2024) & (K Units)
Table 60. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2025-2030) & (K Units)
Table 61. North America Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 62. North America Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 63. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2024) & (K Units)
Table 64. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2025-2030) & (K Units)
Table 65. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2024) & (K Units)
Table 66. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2025-2030) & (K Units)
Table 67. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2024) & (K Units)
Table 68. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2025-2030) & (K Units)
Table 69. Europe Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 70. Europe Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 71. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2024) & (K Units)
Table 72. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2025-2030) & (K Units)
Table 73. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2024) & (K Units)
Table 74. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2025-2030) & (K Units)
Table 75. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2019-2024) & (K Units)
Table 76. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2025-2030) & (K Units)
Table 77. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2019-2024) & (USD Million)
Table 78. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2025-2030) & (USD Million)
Table 79. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2024) & (K Units)
Table 80. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2025-2030) & (K Units)
Table 81. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2024) & (K Units)
Table 82. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2025-2030) & (K Units)
Table 83. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2019-2024) & (K Units)
Table 84. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity by Country (2025-2030) & (K Units)
Table 85. South America Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 86. South America Wet Age-Related Macular Degeneration Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 87. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2019-2024) & (K Units)
Table 88. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Type (2025-2030) & (K Units)
Table 89. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2019-2024) & (K Units)
Table 90. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Application (2025-2030) & (K Units)
Table 91. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2019-2024) & (K Units)
Table 92. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity by Region (2025-2030) & (K Units)
Table 93. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2019-2024) & (USD Million)
Table 94. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Consumption Value by Region (2025-2030) & (USD Million)
Table 95. Wet Age-Related Macular Degeneration Treatment Raw Material
Table 96. Key Manufacturers of Wet Age-Related Macular Degeneration Treatment Raw Materials
Table 97. Wet Age-Related Macular Degeneration Treatment Typical Distributors
Table 98. Wet Age-Related Macular Degeneration Treatment Typical Customers
List of Figures
Figure 1. Wet Age-Related Macular Degeneration Treatment Picture
Figure 2. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Type in 2023
Figure 4. Lucentis Examples
Figure 5. Eylea Examples
Figure 6. Avastin Examples
Figure 7. Others Examples
Figure 8. Global Wet Age-Related Macular Degeneration Treatment Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Application in 2023
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Other Examples
Figure 13. Global Wet Age-Related Macular Degeneration Treatment Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Wet Age-Related Macular Degeneration Treatment Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity (2019-2030) & (K Units)
Figure 16. Global Wet Age-Related Macular Degeneration Treatment Average Price (2019-2030) & (US$/Unit)
Figure 17. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Wet Age-Related Macular Degeneration Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Wet Age-Related Macular Degeneration Treatment Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Wet Age-Related Macular Degeneration Treatment Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Wet Age-Related Macular Degeneration Treatment Average Price by Type (2019-2030) & (US$/Unit)
Figure 32. Global Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Wet Age-Related Macular Degeneration Treatment Average Price by Application (2019-2030) & (US$/Unit)
Figure 35. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Region (2019-2030)
Figure 55. China Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Wet Age-Related Macular Degeneration Treatment Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Wet Age-Related Macular Degeneration Treatment Market Drivers
Figure 76. Wet Age-Related Macular Degeneration Treatment Market Restraints
Figure 77. Wet Age-Related Macular Degeneration Treatment Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Wet Age-Related Macular Degeneration Treatment in 2023
Figure 80. Manufacturing Process Analysis of Wet Age-Related Macular Degeneration Treatment
Figure 81. Wet Age-Related Macular Degeneration Treatment Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Roche Novartis Regeneron Pharmaceuticals Bayer HealthCare Kanghong Pharma
Related Reports
17 Jan 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
